Laboratory operator Quest reports cyber breach affecting patient records

By Reuters News

Oct 22 (Reuters) - Quest Diagnostics DGX.N on Thursday said it learned of unauthorized access to its Quanum LSM system, which some clients use to place test orders, receive and look up results.

The breach adds to a growing number of cyberattacks on the healthcare sector, including those on medical device makers Abbott ABT.N, Stryker SYK.N, Medtronic MDT.N and Boston Scientific BSX.N. Drugmaker Novo Nordisk NOVOb.CO and drug-delivery equipment supplier West Pharmaceutical Services WST.N have also faced threats.

  • While the full scope of unauthorized access remains under investigation, at this time Quest believes that an unauthorized party accessed certain patient records

  • The company disclosed in a regulatory filing that it learned of the incident on Wednesday and has notified federal law enforcement authorities and initiated cybersecurity incident response procedures

  • This incident has not materially disrupted the company's business operations, it said

  • Quest also reported third-quarter earnings, with revenue of $3.10 billion, compared to estimates of $3.05 billion, as per LSEG data

  • Quest shares fell 3.7% to $230 in premarket trading

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.